13 reports

They' re striving toward this goal through public/ private partnerships like SECURE THE FUTURE, their pioneering $## million HIV/ AIDS program in Africa, and through their patient assistance programs.

  • Bladder Cancer
  • China
  • Demand
  • Trade
  • Sanofi-Synthelabo Inc.

They' re striving toward this goal through public/ private partnerships like SECURE THE FUTURE, their pioneering $## million HIV/ AIDS program in Africa, and through their patient assistance programs.

  • Bladder Cancer
  • China
  • Bristol-Myers Squibb China Inc Ltd
  • Sanofi-Synthelabo Inc.
  • Schering-Plough Corporation
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATION, H2 2016
  • PIPELINE BY ALTOR BIOSCIENCE CORP, H2 2016

The preliminary results from these collaborations are very encouraging and indicate that ALT-## has substantial potency against a variety of solid tumors as well as HIV infection in experimental models.

  • Bladder Cancer
  • Cancer
  • Interleukin
  • Therapy
  • Altor BioScience Corporation
  • MYELODYSPLASTIC SYNDROME
  • Bladder Cancer
  • Cancer Immunotherapy
  • Hospital
  • Lung Cancer
  • MedImmune, LLC
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATION, H2 2016

Results were presented in a poster entitled " AR-##, a Novel First in Class Host Cell Targeting Therapeutic Candidate with Potent Activity Against HIV Multidrug Resistant Strains in vitro, " during the ##th European AIDS Conference, which is hosted by the European

  • Bladder Cancer
  • Hospital
  • Pharmaceutical
  • United States
  • World
  • ALT-803 - DRUG PROFILE

P-MAPA was also under development for the treatment for HIV.

  • Bladder Cancer
  • Cancer
  • United States
  • Product Initiative
  • Merck & Co., Inc.
  • 3. GDCT ID is the unique ID of GlobalData's Pharma Intelligence Center clinical trial database

HIV-## Patients with Advanced Solid Tumors Durvalumab in Solid Tumors GDCT## NCT##, GECP ##/ ##_DURVAST; GECP## / ##; 2016-##-##; EudraCT-2016-##-## Oncology Anal Cancer, Bladder Cancer, Breast Cancer, Cervical Cancer, Gastric Cancer, Head And Neck Cancer, Human Immu

  • Bladder Cancer
  • Clinical Trial
  • Monoclonal Antibody
  • World
  • Product Initiative
  • 5. All the trials included are unique trials.

HIV-## Patients with Advanced Solid Tumors Durvalumab in Solid Tumors GDCT## NCT##, GECP ##/ ##_DURVAST; GECP## / ##; 2016-##-##; EudraCT-2016-##-## Oncology Anal Cancer, Bladder Cancer, Breast Cancer, Cervical Cancer, Gastric Cancer, Head And Neck Cancer, Human Immu

  • Bladder Cancer
  • Monoclonal Antibody
  • World
  • Product Initiative
  • Merck & Co., Inc.
  • ALT-803 - DRUG PROFILE
  • ALT-803 - DRUG PROFILE

National Institutes of Health. ##-Nov-2017 HIV & AIDS Malignancy Branch at the National Cancer Institute reported that it will present late breaking results from the first ## patients on a Phase I study of pembrolizumab in patients with HIV and advanced cancers at the

  • Bladder Cancer
  • Cell Therapy
  • North America
  • United States
  • Product Initiative

This agreement enables Viriom and Roche to develop new treatments for HIV/ AIDS.

  • Bladder Cancer
  • Diagnostics
  • United States
  • Company
  • Hoffmann-La Roche Inc.
  • ALT-803 - DRUG PROFILE

TEN PTS (ONE HIV+) REMAIN ON STUDY [## PTS FOR ## MONTHS (M)].

  • Bladder Cancer
  • Monoclonal Antibody
  • United States
  • Company
  • Product Initiative

" More people lose their lives to tuberculosis than to HIV/ AIDS, and yet this is usually a curable and preventable disease, " said John Bishop, Cepheid' s Chairman and Chief Executive Officer.

  • Bladder Cancer
  • Infectious Disease
  • Point Of Care Testing
  • United States
  • Cepheid
  • ALT-803 - DRUG PROFILE

Its product serves various therapeutic areas such as nonsmall cell lung cancer, HIV infection, parasitic infections and others.

  • Bladder Cancer
  • Pharmaceutical
  • Therapy
  • United States
  • Product Initiative